Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of edoxaban in advanced chronic kidney disease patients with atrial fibrillation
2019-003100-13Phase 2Terminated
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of edoxaban in Atrial fibrillation (AFib) (3 arms), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Edoxaban AUC0-24 at steady state. Started Apr 2020; status: terminated.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2019-003100-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003100-13.